Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer

Recruiting now

Conditions studied: Prostate Cancer After a Radical Treatment, Biochemical Recurrence of Malignant Neoplasm of Prostate, Biochemical Persistence of Prostate Cancer

In brief

Following numerous retrospective studies and Phase-3-Studies with promising results, \[18F\]PSMA-1007 has been approved by european authorities. Therefore, it is a growing deployment of this diagnostic method anticipated. This study aims to investigate the diagnostic performance and clinical impact in a real-world-evidence in the context of regular clinical care. The evidence generated by this approach is supposed to assist in optimizing the management of prostate cancer patients.

Key facts

Study ID

NCT06657131

Run by

Heinrich-Heine University, Duesseldorf

People needed

250

Starts

2024-11-01

Expected to finish

2028-11-30

Last updated by the study team

2025-01-17

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Informed Consent
• Conduct of [18F]PSMA-1007 PET Imaging in the context of regular clinical care

You may not qualify if…

• Technical Flaws in the acquisition protocol

Where it is running

• Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf — Düsseldorf, North Rhine-Westphalia, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.